Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases

K Liepe*,1, J Kropp, R Runge and J Kotzerke
1Department of Nuclear Medicine, University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany

Rhenium-188-HEDP (188Re-HEDP) is a new and attractive radiopharmaceutical for the treatment of metastatic bone pain. As a product of 188W/188Re generator, it is convenient for clinical therapeutic use with a short physical half-life of 16.9 h and a maximal $\beta$-energy of 2.1 MeV. We investigated the effect of 188Re-HEDP on pain relief, analgesic intake and impairment of bone marrow function in 27 patients with bone metastases induced from prostate cancer. All patients were interviewed using a standardised set of questions before, and after therapy for 12 weeks. The patients were treated with 2700–3459 MBq of 188Re-HEDP. Blood samples were taken weekly for 12 weeks, and a blood count was performed. Patients described an improvement on the Karnofsky performance scale from 74 ± 7 to 85 ± 9% 12 weeks after therapy ($P = 0.001$). The pain score showed a maximum decrease from 44 ± 18 to 27 ± 20% in the third to the eight week after therapy ($P = 0.009$). Seventy-six percent of the patients described a pain relief without increase of analgesic intake. Twenty percent of the patients could discontinue their analgesics and were pain free. Mean platelet count decreased from $(286 ± 75) \times 10^3$ to $(215 ± 92) \times 10^3$ $\mu l^{-1}$, and mean leucocyte count from $(7.7 ± 1.5) \times 10^3$ to $(6.0 ± 1.9) \times 10^3$ $\mu l^{-1}$ in the second to the fourth week after therapy. The maximal differences between the values of platelets and leucocytes before and after therapy were not statistically significant ($P = 0.021$ and 0.094). In conclusion, 188Re-HEDP is an effective radiopharmaceutical used in the palliative treatment of metastatic bone pain in prostate cancer and shows minimal bone marrow toxicity.

British Journal of Cancer (2003) 89, 625–629. doi:10.1038/sj.bjc.6601158 www.bjcancer.com

© 2003 Cancer Research UK

Keywords: rhenium-188-HEDP; prostate cancer; bone metastases; therapeutic efficiency

Prostate cancer is the second common cause of cancer mortality in men in the UK and in the US (American Cancer Society, 1991; Office for National Statistics Series, 1996). Prostate cancer accounts for 17% of malignant diseases in men >50 years in Germany (‘Krebsregister in Deutschland’, 1999) with a 5-year survival rate of 70%.

The skeleton is the most common site for prostatic metastases. The major mechanism of pain from small metastases appears to be the stimulation of nerve endings in the endosteum by a variety of chemical mediators. Larger bone metastases produce stretching of the periosteum that leads to pain (Nielsen et al, 1991). Resulting bone pain interferes with the patient’s quality of life and requires effective treatment. Unfortunately, various nonradionuclide modalities such as analgesics, hormone therapy, orchidectomy, cytostatic and cytotoxic drugs, bisphosphonates and surgery are not effective in all cases, especially in the late stage of the disease (McEwan, 1998; Debes and Tindall 2002; Gilligan and Kantoff, 2002). External-beam radiotherapy is suitable only for well-defined localised bone metastases. Extended field radiation may be useful in patients with diffuse metastases, but is often accompanied by serious side effects (Lewington, 1993). Therefore, systemic radionuclide therapy must be considered as a valuable and effective method of treatment in patients with widespread skeletal metastases.

The various radiopharmaceuticals that are used for palliative treatment of bone metastases include strontium-89 (Pecher, 1942) phosphorus-32 (Friedell and Storaasli, 1950), iodine-131-BDP

(Eisenhut et al, 1986), yttrium-90 (Kutzner et al, 1991), rhenium-186-HEDP (Maxon et al, 1990) and samarium-153-EDTMP (Turner et al, 1989). More recently, tin-17m-DTPA (Atkins et al, 1989) rhenium-188-HEDP (Palmedo et al, 1995) and rhenium-188-DSA (Blower et al, 2000) have been reported to be effective for bone pain palliation.

We have had more than 5 years experience in the use of 188Re-HEDP for the palliative treatment of bone metastases. Rhenium-188-HEDP has a rapid renal excretion (40 ± 12% of administered activity within the first 8 h), leading to a low radiation dose to the whole body (0.07 ± 0.02 mGy MBq$^{-1}$) and a relatively short biological half-life (51 ± 43 h) in comparison to the half-life within bone metastases (269 ± 166 h) (Liepe et al, 2003). The favourable physical characteristics of the radionuclide for its use in palliative therapy are a short physical half-life of 16.9 h and a maximal $\beta$-energy of 2.1 MeV with a 15% $\gamma$-component of 155 keV. This $\gamma$-component allows the control of tissue distribution after therapy. As a product from in-house 188W/188Re generator, similar to a technetium generator, 188Re-HEDP show a vantage availability. The long useful shelf-life of the generator leads to lower costs in comparison to other radiopharmaceuticals like strontium-89, rhenium-186-HEDP and samarium-153-EDTMP.

**MATERIALS AND METHODS**

**Preparation of 188Re-HEDP**

Rhenium-188-HEDP was prepared as previously described by Lin et al (1997) and Palmedo et al (2000). 188Re-perrhenate was...
obtained from a 38 GBq alumina-based $^{188}$W/$^{188m}$Re generator (Knapp et al, 1997) (Oak Ridge National Laboratory, Oak Ridge, USA). The generator was eluted with 20 – 25 ml of 0.9% saline. The generator eluates were concentrated to about 1.2 ml using a tandem cation/anion concentration system (Guhlke et al, 1998, 2000), which consists of an Ag Plus cartridge (Alltech Associates, Deerfield, IL, USA) attached to a three-way stopcock connected at the outlet to the QMA anion trapping column SepPak (Waters Corporation, Milford, MA, USA) anion-exchange column. The concentration system was housed in a Lucite shield.

In total, 8.3 mg HEDP (Fluka Chemie AG, Buchs, Switzerland), 3.0 mg genitric acid (Sigma-Aldrich, Steinheim, Germany) and 3.9 mg stannous chloride dihydrate (Merck, Darmstadt, Germany) were weighed in kit vials and mixed with 1.0 ml of carrier-added $^{188}$Re-generator eluate (10 µl ReO4 Aldrich, 100 µmol ml$^{-1}$ physiological saline). The solution was heated at 96 – 100°C for 15 min. After cooling to room temperature, 1 ml of a sterile 0.3 m sodium hydroxide solution was added to adjust the pH to a range of 5 – 6.

Quality control of carrier-added $^{188}$Re-HEDP was performed with thin layer chromatography using silica gel (ITLC-SG) strips (Gelman, Ann Arbor, MI, USA). In addition, anion exchange chromatography based on gradient elution with increasing concentrations of NaCl solutions using a QMA SepPak was used. The radiochemical purity determined by both procedures (ITLC and anion exchange) was more than 90%. Sterility and pyrogenicity tests were performed for each preparation.

Patients

In this phase II study, 27 patients with multiple bone metastases from prostate cancer and pain well-controlled by conventional analgesia were included. In previous dose-escalation studies (Palmedo et al, 2000), an activity of 3300 MBq of $^{188}$Re-HEDP was determined as suitable for bone pain palliation. We evaluated the effect of $^{188}$Re-HEDP on pain relief, reduction of analgesics and changes in quality of life. Before and for 12 weeks after the $^{188}$Re-HEDP therapy, weekly interviews with a standardised set of questions concerning pain relief with the visual analogue scale (VAS) from 0 to 100% (Serafini et al, 1998; Kraeber-Bodere et al, 2000), analgesics and Karnofsky performance scale were conducted weekly (Figure 1). A pain relief $\leq$ 25% on the VAS at least in two consecutive weeks without increase of analgesics was used as criteria for response.

Blood counts were obtained to evaluate the impairment of bone marrow function within 6 weeks after therapy and in the 12th week. For the assessment of toxicity, the toxicity criteria of the World Health Organization (1979) were used. According to this toxicity scale, platelet counts of 74 – 99 $\times 10^{3}$ $^{-1}$, 50 – 74 $\times 10^{3}$ $^{-1}$, 25 – 49 $\times 10^{3}$ $^{-1}$ and below 25 $\times 10^{3}$ $^{-1}$ correspond to a toxicity grade of 1, 2, 3 and 4, respectively. The maximum decrease was calculated by comparison of the level of blood counts before therapy (baseline) with the lowest level within 12 weeks. All patients underwent a $^{99m}$Tc-HMIDP bone scan within 1 month before and 3 months after therapy to obtain a possible decrease of the mass of bone metastases. In a single case, we had also a later bone scan.

Criteria for patient inclusion in the study were

- positive $^{99m}$Tc-HMIDP bone scan with at least three lesions;
- bone pain symptoms requiring the long-term use of analgesics;
- sufficient bone marrow function with a platelet count $\geq$ 100 $\times 10^{3}$ $^{-1}$, leucocyte count $\geq$ 3.0 $\times 10^{3}$ $^{-1}$ and haemoglobin $\geq$ 6.0 mmol l$^{-1}$ (9.67 g dl$^{-1}$);
- normal renal function.

Criteria for exclusion were

- metastatic bone fractures;
- spinal cord compression;
- soft tissue tumours elsewhere causing nerve compression.

Chemotherapy and bisphosphonate therapy were discontinued 4 weeks before the administration of the radiopharmaceutical. In accordance with the Helsinki declaration, all patients were informed comprehensively about the study and possible side effects and were provided with a leaflet. Consent approval had been obtained from the local ethics committee.

Statistics

Data are presented as mean $\pm$ S.D. For determining a significant change in the visual analogue scale and Karnofsky performance scale, we used the Student’s $t$-test. Two-tailed $P$-values less than 0.05 were considered to indicate statistical significance.

RESULTS

Twenty-seven patients (mean age = 68, range 55 – 87 years) with disseminated bone metastases from prostate cancer received a single intravenous injection of $^{188}$Re-HEDP. The administered activity ranged from 2700 to 3587 MBq (mean dose = 3245 $\pm$ 356 MBq). All patients had analgesics. Patients were hospitalised for 2 days for the $^{188}$Re-HEDP therapy due to a German radiation protection law. All patients had a single therapy. All patients received a hormone therapy for at least 6 months before therapy and also during the post-therapy observation period. Nineteen patients had been treated with chemotherapy and seven patients external beam radiation prior to the $^{188}$Re-HEDP therapy. All these treatments were finished at least 5 months before the $^{188}$Re-HEDP therapy. It is unlikely that these various preceding therapies modified or altered the observed therapeutic effect in this study.

Twenty-five patients were included in the evaluation of the therapeutic efficiency of the $^{188}$Re-HEDP therapy. Two patients were excluded: one patient because of incomplete follow-up and one died 9 weeks after treatment from the cancer, unrelated to the therapy.

The Karnofsky performance scale increased from 74 $\pm$ 7% before therapy to 85 $\pm$ 9% at 12 weeks after therapy (Figure 1). This increase was statistically significant ($P = 0.001$). Pain relief $\leq$ 25% on the VAS at least in two consecutive weeks without increase of analgesics intake was achieved in 76% of patients (19 out of 25). Five from these 19 patients were pain free (20%). The VAS showed a decrease from 44 $\pm$ 18 to 31 $\pm$ 25% at the 12th week after $^{188}$Re-HEDP therapy ($P = 0.009$) (Figure 2). The maximum of pain relief was described within the 3rd to the 8th week (27 $\pm$ 20%).

There was no evidence of either local or systemic intolerance to treatment with $^{188}$Re-HEDP, while a flare reaction with an increase in...
of pain within 14 days after therapy was noted in 16% of patients. Most of the patients showed a grade I anaemia according to the WHO criteria (World Health Organization, 1979) before injection, with no significant worsening within 12 weeks after therapy (haemoglobin 7.6 ± 2.6 before and 7.1 ± 3.0 mmol l⁻¹ 12 weeks after treatment). The maximum decrease in one patient from the baseline value was 6.8 to 5.7 mmol l⁻¹. There was mild thrombocytopaenia (grade I thrombocytopaenia in two patients and grade II in one patient), but no evidence of unacceptable toxicity (defined as grade III or IV toxicity). Thrombocytopaenia was reversible within 12 weeks after therapy. The platelet counts decreased from a baseline value of 286 ± 75×10⁹ l⁻¹ to a maximum of 218 ± 83×10⁹ l⁻¹ at 2.7 ± 0.9 weeks after therapy (Figure 3). The patient with a thrombocytopaenia grade II had a platelet count of 62×10⁹ l⁻¹. Grade I leucopenia was observed only in one patient (2.9×10⁹ l⁻¹) and was also reversible within 12 weeks. The leucocyte counts decreased from a baseline value of 7.4 ± 1.5×10⁹ l⁻¹ – 6.0 ± 1.9×10⁹ l⁻¹ at 3.0 ± 0.6 weeks after therapy (Figure 4).

Generally, over the follow-up period, there were no significant changes in the PSA levels, but in individual cases a decrease was noted (PSA level: 159 ± 151 vs 155 ± 203 ng ml⁻¹; P = 0.96).

No patient showed a decrease in the bone metastases demonstrated on the ⁹⁹ᵐTc-HMDP bone scans before treatment when compared to the scans obtained 3 months post-treatment. The bone scan index (BSI) level (Blake et al, 1986) in the group of patients with no response to the ¹⁸⁸Re-HEDP therapy was 54 ± 19, in the group of patients with a good response 37 ± 14 and in pain-free patients 36 ± 5 (P = 0.24). In three of the patients, there was a decrease of the number of bone metastases with a mean decrease of the BSI level from 33 ± 18 before treatment to 19 ± 11 within 1 year after ¹⁸⁸Re-HEDP therapy. One of these showed an improvement of the BSI from 45 to 17 six months after therapy (Figure 5A, B). The

Figure 2  Time course of the pain at visual analogue scale before and within 12 weeks after ¹⁸⁸Re-HEDP therapy (with s.d.’s).

Figure 3  Bone marrow impairment due to ¹⁸⁸Re-HEDP expressed as platelet counts in serial blood samples (with s.d.’s).

Figure 4  Bone marrow impairment due to ¹⁸⁸Re-HEDP expressed as leucocyte counts in serial blood samples (with s.d.’s).

Figure 5  (A) Bone scan of a 71-year-old patient with bone metastases induced by prostate cancer one month before ¹⁸⁸Re-HEDP therapy (bone scan index = 45). The Karnofsky performance scale was 70% and the pain of the visual analogue scale = 50%. (B) Bone scan of the same patient 6 months after therapy (bone scan index = 17). The Karnofsky performance scale was 80% and the pain of the visual analogue scale = 25%.
71-year-old patient was treated by bisphosphonate therapy (with etidronacid), nonsteroid antiinflammatorys, and mild analgesics (dextropropoxyphene) and an analogue of the luteinising hormone (dehydroepiandrosterone) from the beginning of the disease. Under this therapy, the patient described a progression of the disease with an increase in pain symptoms. Within 12 weeks of the 188Re-HEDP therapy, the Karnofsky performance scale increased from 70 to 80%, and the pain at the VAS decreased from 50 to 25%.

DISCUSSION
Systemic radionuclide therapy with β-emitting radiopharmaceuticals represents a therapeutic option in the management of intractable metastatic bone pain and has been used since 1942 (Pecher, 1942). Nowadays, strontium-89, rhenium-186-HEDP and samarium-153-EDTMP are the preferred radiopharmaceuticals. From a theoretical point of view, 188Re-HEDP offers potential as a new and attractive radiopharmaceutical for the treatment. As a generator product it has an excellent availability that permits on-site labelling with the routinely used 99mTc-generator resulting in low costs.

In the literature there are few reports about the therapeutic efficiency of 188Re-HEDP in only small patient groups (Maxon et al., 1998; Palmedo et al., 2000), which reported a response rate of 70–80%. In 23 patients with bone metastases from a variety of primary tumours, 188Re-HEDP therapy was able to reduce analgesic intake in 82% of patients (Chen, 2000). In addition, 70% of the patients had a significant and 22% a minor improvement of quality of life. Using 188Re-HEDP at an activity of 1100 MBq, a response rate of 80% was obtained in a cohort of 61 patients with various primary tumours (Li et al., 2001). Studies with a large number of patients exist for patients treated with strontium-89, rhenium-186-HEDP and samarium-153-EDTMP. In a multicentre study with 818 patients treated with strontium-89 and rhenium-186-HEDP Dafermou et al. (2001) described pain relief in 81% of the patients with prostate cancer and 27% of these were pain free. Enrique et al. (2002) showed a response rate of 73% in a cohort of 417 patients treated with samarium-153-EDTMP at an activity varying between 18.5 and 55 MBq kg−1 body weight. In our study using 188Re-HEDP, pain relief was demonstrated in 76% of patients and 20% from these were pain free without increase of analgesia. In addition, a significant increase of the Karnofsky performance scale of 11% compared to the initial value within 12 weeks was observed. In comparison, the dose-escalation study in a small number of patients (n = 6) using 3300 MBq of 188Re-HEDP (Palmedo et al., 2000) showed a lower response rate.

In the present study, no unacceptable toxicity was observed. There were two patients with thrombocytopenia grade I and one with thrombocytopenia grade II. A mean decrease of platelet counts of 30±14% from the baseline value was noticed, maximally at 2.7±0.9 weeks after therapy. The maximum decrease in one patient was down to 62±10×10⁹ l−1. The leucocyte counts showed a mean decrease of 25±17% from the baseline value (Figure 4) with a maximum at 3.0±0.6 weeks. Only one patient had a leucopenia grade I. The bone marrow toxicity of 188Re-HEDP showed no correlation to the extension of bone metastases in the 99mTc-HMDP bone scan or the level of the BSI. Similar results are shown in the dose-escalation study with 3300 MBq 188Re-HEDP of Palmedo et al. (2000), who observed two patients with thrombocytopenia grade I and one with grade II. In the group with 4400 MBq, an unacceptable toxicity was observed in three out of eight patients, two with thrombocytopenia grade IV and one with thrombocytopenia grade III. Therefore, an activity of 3300 MBq of 188Re-HEDP is generally accepted in the palliative treatment of bone metastases.

The mean PSA level was unchanged during the follow-up (159±151 vs 155±203 ng ml−1; P = 0.96, but in individual cases there was a measurable decrease in the PSA.

While radionuclide therapy for bone pain is mainly palliative, occasionally cure can be obtained and in the three cases described in this study there were decreases in bone metastases shown on conventional 99mTc-HMDP bone scan with concomitant decrease in the BSI level from 33±18 to 19±11 within 1 year after treatment (Robinson et al., 1989; Mertens et al., 1992; Liepe et al., 2000). Of these patients, two were pain free.

In general, large bone metastases demonstrated on the 99mTc-HMDP bone scans correlate well with sites of pain. In patients where there was no response to therapy, a higher BSI level was seen (BSI = 51±19) compared to those patients where a favourable response occurred or the patients were pain free (BSI = 33±11) (P = 0.08). Other authors also described a higher response rate to treatment in early bone metastases, favouring active treatment in such cases (Kraeber-Bodere et al., 2000; Dafermou et al., 2001). A previous dosimetry study gave the radiation absorbed dose for 188Re-HEDP as 11.8±6.2 Gy (range: 1.2–31.3 Gy) for the bone metastases, and 1.9±0.7 Gy (1.3–3.6 Gy) for the red bone marrow (Liepe et al., 2003). These values are comparable with the dosimetry for 188Re-HEDP (26 Gy for the bone metastases and 1.8 Gy for the red bone marrow) and also with the therapeutic effect and the bone marrow toxicity of 186Re-HEDP (Maxon et al., 1990, 1998).

In conclusion, 188Re-HEDP is effective in the palliation of metastatic bone pain, without induction of severe side effects.

ACKNOWLEDGEMENTS
The research at the Oak Ridge National Laboratory (ORNL) was supported by the US Department of Energy (DOE), under contract DE-AC05-00OR22725 with UT-Battelle, LLC.

REFERENCES
American Cancer Society (1991) Cancer Facts and Figures – 1991, P. 5
Atlanta, GA: ACS
Atkins HL, Mausner LF, Srivastava SC, Meiken GE, Cabahug CJ, D’Alessandro T (1995) Tin-117m+43-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med 36: 725–729
Blake GM, Zivinovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12: 447–454
Blewer PJ, Kettle AG, O’Doherty MJ, Coakley AJ, Knapp Jr FF (2000) 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med 27: 1405–1409
Chen SL (2000) Treatment of metastatic bone pain with 188Re-HEDP. J Nucl Med 5 (Suppl): 265
Dafermou A, Colamussi P, Giganti M, Cittani C, Bestagno M, Piffanelli A (2001) A multicentre observation study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28: 788–798
Debes JD, Tindall DJ (2002) The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 187: 1–7
Eisenhut M, Fritz P, Kimmig B, Wingen F, Krempen B (1986) Iodine-131–Ibritter for treatment of carcinoma of the breast with widespread metastasis in bone. J Nucl Med 27: 447–454
Eisenhut M, Fritz P, Kimmig B, Wingen F, Krempen B (1986) Iodine-131–Ibritter for treatment of carcinoma of the breast with widespread metastasis in bone. J Nucl Med 27: 447–454
Enrique O, Zhonyun P, Prma EP, Pusuwann P, Riccabona G, Tian J-H, Obalda J, Padhy AK (2002) Efficacy and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med 1: 29–34
Friedell HL, Storaasli JP (1950) The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastasis in bone. AJR 64: 559–575
Gilligan T, Kantoff PW (2002) Chemotherapy for prostate cancer. *Urology* 60: 94 – 100

Guhlke S, Beets AL, Oetjen K, Mirzadeh S, Biersack HJ, Knapp FF (2000) Simple new method for effective concentration of $^{188}$Re solutions from alumina-based $^{188}$W-$^{188}$Re-generator. *J Nucl Med* 41: 1271 – 1278

Knapp Jr FF, Beets AL, Guhlke S, Zamora PO, Bender H, Palmedo A, Biersack HJ (1997) Development of the alumina-based tungsten-$^{188}$/rhenium-$^{188}$ generator and use of rhenium-$^{188}$-labeled radiopharmaceuticals for cancer treatment. *Anticancer Res* 17: 1783 – 1796

Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I (2000) Treatment of bone metastases of prostate cancer with strontium-$^{89}$ chloride: efficacy in relation to the degree of bone involvement. *Eur J Nucl Med* 27: 1487 – 1493

Krebsregister in Deutschland (1999) *Cancer in Germany.* Robert Koch Institute. Saarbrücken, Germany

Kutzner J, Hahn K, Grimm W, Brod K, Rössler HP (1991) Treatment of bone metastases of the prostate with yttrium isotope. In *Radioisotopes for Prostatic Gland*, Limouris G, Shukla SK (eds.) pp 171 – 183. Rome

Lewington VJ (1993) Targeted radionuclide therapy for bone metastases. *Eur J Nucl Med* 20: 66 – 74

Li S, Liu J, Tian M, Wang J, Zheng X (2001) Rhenium-$^{188}$ HEDP to treat painful bone metastases. *Clin Nucl Med* 26: 919 – 922

Lin W, Lin C, Yeh S, Hsieh B, Tsai Z, Ting G, Yen T, Wang S, Knapp FF, Stabin M (1997) Rhenium-$^{188}$ HEDP: a new generator-produced radiotherapeutic drug of potential value for treatment of bone metastases. *Eur J Nucl Med* 24: 590 – 595

Liepe K, Hliscs R, Kropp J, Runge R, Knapp Jr FF, Franke WG (2003) Dosimetry of $^{188}$re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. *J Nucl Med* 44: 953 – 960

Liepe K, Kropp J, Hliscs R, Franke WG (2000) Significant reduction of the mass of bone metastasis 1 year after rhenium-$^{186}$ HEDP pain palliation therapy. *Clin Nucl Med* 25: 1 – 4

Maxon HR, Schroder L, Thomas SR (1990) Re-$^{186}$(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. *Radiology* 176: 155 – 159

Maxon HR, Schroder LE, Washburn LC, Thomas SR, Samaratunga RC, Binakiewicz D, Moulton JS, Cummings D, Ehrhardt GJ, Morris V (1998) Rhenium-188(Sn)HEDP for treatment of osseous metastases. *J Nucl Med* 39 (4): 659 – 663

McEwan AJ (1998) Palliative therapy with bone seeking radiopharmaceuticals. *Cancer Biother Radiopharm* 13: 413 – 426

Mertens WC, Porter AT, Reid RH, Powe JE (1992) Strontium-$^{89}$ and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. *J Nucl Med* 33: 1437 – 1443

Nielsen OS, Munro AJ, Tannock IF (1991) Bone metastases: pathophysiology and management policy. *J Clin Oncol* 9: 509 – 524

Office for National Statistics Series DH. No 23 (1996) *Mortality Statistics by Cause: England and Wales 1996.* London, UK: Her Majesty’s Stationary Office

Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp Jr FF, Biersack HJ (2000) Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. *Eur J Nucl Med* 27 (2): 123 – 130

Pecher P (1942) Biological investigation with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. *Univ Calif Publ Pharmacology* 2: 117 – 149

Robinson G, Blake G, Preston DF, McEwan A, Spicer J, Martin N, Wegast A, Ackery D (1989) Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. *Radiographics* 9: 271 – 281

Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahrmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. *J Clin Oncol* 16: 1574 – 1581

Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA (1989) A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. *J Clin Oncol* 7: 1926 – 1931

World Health Organization (1979) *WHO Handbook for Reporting Results of Cancer Treatment.* Geneve, Switzerland: World Health Organization, Offset publication 48